Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 26:10:1445-53.
doi: 10.3762/bjoc.10.148. eCollection 2014.

Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates

Affiliations

Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates

Marian M J H P Willems et al. Beilstein J Org Chem. .

Abstract

The covalent attachment of an innate immune system stimulating agent to an antigen can provide active vaccine modalities capable of eliciting a potent immune response against the incorporated antigen. Here we describe the design, automated synthesis and immunological evaluation of a set of four muramyl dipeptide-peptide antigen conjugates. Muramyl dipeptide (MDP) represents a well-known ligand for the intracellular NOD2 receptor and our study shows that covalently linking an MDP-moiety to an antigenic peptide can lead to a construct that is capable of stimulating the NOD2 receptor if the ligand is attached at the anomeric center of the muramic acid. The constructs can be processed by dendritic cells (DCs) and the conjugation does not adversely affect the presentation of the incorporated SIINFEKL epitope on MHC-I molecules. However, stimulation of the NOD2 receptor in DCs was not sufficient to provide a strong immunostimulatory signal.

Keywords: NOD2 receptor; automated synthesis; glycopeptide; innate immunity; muramyl dipeptide; solid phase synthesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MDP-antigen conjugates 25. DEVA5K = DEVSGLEQLESIINFEKLAAAAAK.
Scheme 1
Scheme 1
a) TMSOTf, DCM, 83%; b) cat. NaOMe, MeOH, quant.; c) CSA, PhCH(OMe)2, MeCN, DMF, 86%; d) (S)-2-chloropropionic acid, NaH, 1,4-dioxane, 93%; e) Boc2O, NH4HCO3, pyridine, 1,4-dioxane, 99%; f) 1) DBU, HOBt, DCM; 2) Fmoc-L-Ala-OH, EDC, DIPEA, DCM, 82%; g) 1) 13, DBU, HOBt, DCM; 2) 12, HATU, DIPEA, DCM, 70%; h) 1) Me3P (solution in THF), DMF, THF, 80%; 2) Fmoc-Glu-(OH)-OAllyl, HATU, DIPEA, DMF, 57%; i) Pd(PPh3)4, Bu3SnH, AcOH, DMF, 72%; j) 60% AcOH, H2O, neopentylglycol, 88%; k) Ac2O, pyridine; l) 20% TFA, DCM, 82% (2 steps); m) NH4OH, MeOH, 87%.
Scheme 2
Scheme 2
a) 20% piperidine, NMP; b) Fmoc SPPS DEVA5K; c) Fmoc-D-isoGln-OH, HCTU, DIPEA, NMP; d) Fmoc-L-Ala-OH, HCTU, DIPEA, NMP; e) 10, HATU, DIPEA, NMP; f) 95% TFA, 2.5% H2O, 2.5% TIS; g) Boc2O, NMP, DIPEA; h) 3% TFA, DCM. i) 16, HATU, DIPEA, NMP; j) 16, DIPEA, HCTU, DMSO, DMF.
Figure 2
Figure 2
Potency of the NOD2-L antigen conjugates 25 in NOD2 transfected HEK cells.
Figure 3
Figure 3
DC activation of the conjugates 25 and reference compounds 29 and 30.
Figure 4
Figure 4
Antigen presentation of the conjugates 25 and reference compounds 29 and 30.

References

    1. O'Neill L A J, Golenbock D, Bowie A G. Nat Rev Immunol. 2013;13:453–460. doi: 10.1038/nri3446. - DOI - PubMed
    1. Lemaitre B, Nicolas E, Michaut L, Reichhart J-M, Hoffmann J A. Cell. 1996;86:973–983. doi: 10.1016/S0092-8674(00)80172-5. - DOI - PubMed
    1. Daftarian P, Sharan R, Haq W, Ali S, Longmate J, Termini J, Diamond D J. Vaccine. 2005;23:3453–3468. doi: 10.1016/j.vaccine.2005.01.093. - DOI - PubMed
    1. Alphs H H, Gambhira R, Karanam B, Roberts J N, Jagu S, Schiller J T, Zeng W G, Jackson D C, Roden R B S. Proc Natl Acad Sci U S A. 2008;105:5850–5855. doi: 10.1073/pnas.0800868105. - DOI - PMC - PubMed
    1. Cai H, Sun Z-Y, Huang Z-H, Shi L, Zhao Y-F, Kunz H, Li Y-M. Chem–Eur J. 2013;19:1962–1970. doi: 10.1002/chem.201203709. - DOI - PubMed

LinkOut - more resources